NCT06506422

Empagliflozin Reversal of Arterial StiffnEss in Aging

SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: University of Missouri-Columbia · Academic / Other
• Sex: All
• Age: 60 Years – 80 Years
• Healthy volunteers: Accepted

Summary

Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.

Detailed description

The investigators will employ a double-blinded randomized placebo control trial to determine the effects of 12 weeks of sodium glucose co-transporter 2 (SGLT2) inhibition with empagliflozin (10 mg daily), or matching placebo. Empagliflozin has been shown to decrease cardiovascular events and arterial stiffness in different populations. Placebo will be included for comparison purposes as empagliflozin is not a standard therapy for aging-associated arterial stiffness.

Conditions

• Aging
• Arterial Stiffness

Interventions

Type	Name	Description
DRUG	Empagliflozin 10 MG	10mg Empagliflozin daily for 12 weeks
DRUG	Placebo	10mg Placebo daily for 12 weeks

Timeline

• Start date: 2024-08-18
• Primary completion: 2028-10-31
• Completion: 2029-02-28
• First posted: 2024-07-17
• Last updated: 2026-02-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study